secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2023-08-02T23:59:59+00:00
Accession:  0001157523-23-001212
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teva Q2 2023 revenue $3.88B, GAAP loss $0.77/sh, non-GAAP EPS $0.56; raises revenue guidance
--------------------------------------------------------------------------------

- Revenue $3.88B (+2% YoY, +4% local currency); AUSTEDO U.S. rev $308M.
- GAAP net loss $863M ($0.77 loss per share) vs $232M loss in Q2 2022.
- Non-GAAP diluted EPS $0.56, down from $0.68 YoY; non-GAAP operating margin 26.1%.
- Free cash flow $632M; operating cash flow $324M.
- FY 2023 revenue guidance raised to $15.0-$15.4B; all other guidance reaffirmed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000115752323001212/0001157523-23-001212-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000115752323001212/a53501990.htm
  HTML page:      https://secwatch.observer/filing/0001157523-23-001212

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer